



Vaccination for adults

Assoc.Prof.Dr.Serhat Birengel, MD AUSM, Department of Infectious Disease and Clinical Microbiolgy birengel@medicine.ankara.edu.tr serhatbirengel@gmail.com

Learning objects

At the end of this part of panel, student,

- describes the importance and necessity of vaccination in adults
- lists the vaccines recommended for adults.
- lists the vaccines for immunocompromised host (ICH) and

healthcare personnel (HCP).

Vaccination = Active immunization

is the **artificial** protection of a person from infectious diseases

giving **microorganism itself** (live-attenuated , death, or toxoid) **or** its **antigenic** structures

by stimulating cellular and humoral immunity

Which one is preferred?



Louis Pasteur (1822-1895)



A Vision to future of humanity



Edward Jenner

(the pioneer of smallpox vaccination and the father of immunology !)

- **1796** → Found vaccine (named **vacca** in Latin =cow)
 - → Smallpox eradicated in 1977 (180 years later !)





Poliomyelitis

- Jonas Salk 1953 → Poliomyelitis vaccine, inactivated.
- Albert Sabin 1961 \rightarrow Poliomyelitis vaccine, live attenuated.
 - 2/3 types of Poliovirus eradicated worldwide at present.
 - There is no paralytic polio in Turkey since 2002.





Proof of success !

The incidence of vaccine-preventable disease (new disease rate detected)

	Annual mor no. of cas	Morbidity	
Disease	20th century	2007	%
Diphtheria	21,053		100
Measles	530,217	43	99.9
Mumps	162,344	800	99.5
Pertussis	200,752	10,454	94.8
Polio (paralytic)	16,316		100
Rubella	47,745	12	99.9
Congenital rubella syndrome	152		99.3
Smallpox	29,005		100
Tetanus	580	➡ 28	95.2
Haemophilus. influenzae (type b and unknown; <5 years)	20,000	⇒ ₂₀₂	⇒ 99

decreased by 99% compared to the 20th century in USA.

Pickering LK. Clin Infect Dis. 2009 Sep 15;49(6):817-40.

Vaccination is a proven application that is useful in all age groups and risk groups.







Rationales for increasing adult vaccination

- Success in child and adolescent vaccination program.
- New vaccines targeted at adults.
- **Recognition of the burden** of adult vaccine-preventable disease.
- **Having risks related to** occupation, life style, pregnancy, travel, DM, ESRD, ...

Disease burden

Death caused by vaccine-preventable diseases in adults

~50.000/year in USA

<u>Influenza</u>:

- → 10-20% / year
- \rightarrow ~ 200,000 hospitalization
- →~ 16.000-20.000 death

Pneumococcal infections occur frequently :

- → 2000-4000 meningitis
- \rightarrow >40.000 bloodstream infections
- ➔ 150.000-300.000 pneumonia

Generally recommended vaccines for adults:

- 1. Hepatitis B (HepB)
- 2. Hepatitis A (HepA)
- 3. Pneumococcal (PCV, PPSV)
- 4. Influenza (Flu)
- 5. Tetanus Diphteria, +/- Pertussis (Td/ap)
- 6-8. Measles, Mumps, Rubella (MMR)
- 9. Varisella, Zoster (VAR, ZVL)
- 10. HPV
- 11. Meningococcal (Men)
- 12. Haemophilus (Hib)

should think separately for each person !

- 1. Primary vaccine series completed ? Further requirements?
- 2. Lack documentation of vaccination
- 3. Lack evidence of past infections?
- 4. Additional risk factors:
 - Underlying diseases/conditions ?
 - HI∧ š
 - ICH S
 - ESRD/HD, CLD, diabetes, asplenia, MSM, ...
 - Pregnancy ? / breast-feeding ?
 - HCP ?
 - Travel ?
 - Animal contacts ?

Table 1 Recommended Adult Immunization Schedule by Age Group, United States, 2020

Vaccine	19–26 years	27–49 years	50-64 years	≥65 years		
Influenza inactivated (IIV) or Influenza recombinant (RIV)		1 dose annually				
Influenza live, attenuated (LAIV)		1 dose annually				
Tetanus, diphtheria, pertussis (Tdap or Td)		1 dose Tdap, then Td or Tdap booster every 10 years				
Measles, mumps, rubella (MMR)		1 or 2 doses depending on indication (if born in 1957 or later)				
Varicella (VAR)	2 d	oses (If born in 1980 or later)	2 do	ses		
Zoster recombinant (RZV) (<i>preferred</i>)			2	doses		
Zoster live (ZVL)			1	dose		
Human papillomavirus (HPV)	2 or 3 doses depending on age at initial vaccination or condition	27 through 45 years				
Recommended vaccination for adults who meet age requirement.						

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended vaccination for adults with an additional risk factor or another indication Recommended vaccination based o shared clinical decision-making No recommendation/ Not applicable

Table 1 Recommended Adult Immunization Schedule by Age Group, United States, 2020

Vaccine	19–26 years	27-49 years	50–64 years	≥65 years		
Pneumococcal conjugate						
(PCV13)			1 4056			
Pneumococcal polysaccharide (PPSV23)	1 or 2 doses depending on indication 1 dose					
Hepatitis A (HepA)	2 or 3 doses depending on vaccine					
Hepatitis B (HepB)	2 or 3 doses depending on vaccine					
Meningococcal A, C, W, Y (MenACWY)	1 or 2 doses depending on indication, see notes for booster recommendations					
Meningococcal B	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations					
(MenB)	19 through 23 years					
<i>Haemophilus influenzae</i> type b (Hib)	1 or 3 doses depending on indication					

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended vaccination for adults with an additional risk factor or another indication Recommended vaccination based of shared clinical decision-making

No recommendation/ Not applicable

should think separately for each person !

- 1. Primary vaccine series completed ? Further requirements?
- 2. Lack documantation of vaccination
- 3. Lack evidence of past infections?
- 4. Additional risk factors:
 - Underlying diseases/conditions ?
 - HI∧ š
 - ICH?
 - ESRD/HD, CLD, diabetes, asplenia, MSM, ...
 - Pregnancy ? / breast-feeding ?
 - HCP ?
 - Travel ?
 - Animal contacts ?

Immunocompromised host

- 1. <u>Stem cell transplant patients</u>
- 2. Congenital or acquired immunodeficiencies
 - Hematologic neoplasms (leucemia, lymphoma, multiple myeloma)
 - Asplenia, splenectomy
 - **HIV infection**, severe combined immunodeficiency, ...
- 3. <u>Immunosuppressive treatments</u>
 - Solid organ transplants (liver, kidney, lung, pancreas, hearth)
 - Chemotherapy, corticosteroids, anti-TNF alfa, ...
- Those with chronic disease and immunosuppression (diabetes mellitus, ESRD, CLD, etc.)

ID risk, morbidity and mortality ?



As a rule, **live vaccines are contraindicated** to immunocompromised host because of virulence and risk of infection (LAIV, MMR, VAR, ZLV, BCG)

Therefore toxoid, inactivated or recombinant vaccines could be done safely in this population

Recommended vaccines for ICH

1. Tdap:

- **Tetanus** (Clostridium tetani) ,
- **Diphteria** (Corynebacterium diphteriae)
- Pertussis (Bordetella pertussis)
- 2. Flu (Influenzavirus): Inactivated form (IIV)
- 3. Pneumococcal (Streptococcus pneumoniae) PPSV, PCV
- 4. HPV (Human papillomavirus)
- 5. Hib (Haemophilus influenzae type b) only for Hematopoietic Stem Cell Transplant (HSCT) recipients

	Vaccine	Pregnancy	Immuno- compromised (excluding HIV Infection)	HIV Infection CD4 count <200 ≥20	Asplenia, complement deficiencies	End-stage renal disease; or on hemodialysis	Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack	Recommended vaccination for adults with an additional risk factor or another indication
	IIV or RIV					1 dose a	evidence of past infection	
LIVE !	LAIV		NOT REC	MMENDED				
	Tdap or Td	1 dose Tdap each pregnancy			1 dos	e Tdap, then Td	Precaution—vaccination might be indicated if benefit	Delay vaccination until after pregnancy if vaccine is
	MMR	NOT R	COMMENDED				of protection outweighs risk of adverse reaction	indicated
LIVE !	VAR	NOT R	COMMENDED				Not recommended/	No recommendation/
	RZV (preferred)	DELAY					contraindicated—vaccine should not be administered	Not applicable
LIVE !	ZVL	NOT R	COMMENDED					
	HPV	DELAY	3 doses throu	;h age 26 year				
	PCV13					1 c		
	PPSV23							
	НерА							
	НерВ							
	MenACWY		1 or 2	oses dependi	g on Indication,	see notes for boo		
	MenB	PRECAUTION		2 01	3 doses dependi	ng on vaccine an		
	HIb		3 doses HSCT ³ recipients only		1 d	ose		

Vaccination timing for ICH

- 1. <u>Stem cell transplant patients</u>
- 2. Congenital or acquired immundeficiencies
 - Hematologic neoplasms (leucemia, lymphoma, multiple myeloma)
 - Asplenia, splenectomy
 - HIV infection, severe combined immunodeficiency, ...

3. <u>Immunosuppressive treatments</u>

- Solid organ (liver, kidney, lung, pancreas, hearth) transplants
- Chemotherapy, corticosteroids, anti-TNF alfa, ...

Those with chronic disease and immunosuppression (diabetes mellitus, CRD, CHD, etc.)

Possible immune suppression time/condition should be considered:



at least 2 wks before



The patient's environmental sources of infection need to be reduced;

- 1. Family members
- 2. Close contacts
- 3. Healthcare personnel

should be advised to vaccinate.

should think separately for each person !

- 1. Primary vaccine series completed ? Further requirements?
- 2. Lack documantation of vaccination
- 3. Lack evidence of past infections?
- 4. Additional risk factors:
 - Underlying diseases/conditions ?
 - HIA Š
 - Immunodeficiency ?
 - ESRD/HD, CLD, diabetes, asplenia, MSM, ...
 - Pregnancy ? / breast-feeding ?

- HCP (Healthcare personnel)?

- Travel ?
- Animal contacts ?



- Doctors
- Nurses
- Dentists
- Medicine, dentistry and nursing students
- Laboratory staff
- Emergency personnel
- Management-related employees

Vaccine	Chronic liver disease	Diabetes	Health care personnel ²	Ven who have sex with men	Recommended vaccination for adults who meet age requirement, lack documentation of indication
IIV or RIV					vaccination, or lack evidence of past infection
LAIV	UTION		1 dose a	nually	
Tdap or Td	r every 10 years				Precaution—vaccination might be indicated if benefit Delay vaccination until after pregnancy if vaccine is
MMR	pending on Ind	lication]	of protection outweighs risk indicated of adverse reaction
VAR	2 doses				Not recommended/ No recommendation/
RZV (preferred)	loses at age ≥50) years			contraindicated—vaccine Not applicable should not be administered
ZVL	ose at age ≥60	years			
HPV	ough age 26 ye	ars			
PCV13					
PPSV23	loses depending	g on age and I	dication		
НерА	r 3 doses depen	ding on vacci	e		
НерВ	r 3 doses depen	iding on vacci	е	1	
MenACWY	dations				
MenB	e notes for boos	ster recommer	dations		
нь					



- with potential exposure to blood or body fluids should be immune to HepB,
- 2. should be offered annual immunization with flu vaccine.
- 3. should be immune to MMR-VAR,
- 4. should **receive** a **one-time dose of Tdap** as soon as possible, unless they are certain that they have received Tdap.

Highly recommended

- 1. HepB
- 2. Flu
- 3. MMR
- 4. Varicella / zoster
- 5. Tdap /Td

HepB vaccination

- A significant risk to HCP 10 times more
- With occupationally exposed to **blood or other infectious** materials or sharps:
 - Needle stick Injuries approximately 70%
 - The rate is higher in education hospitals
 - Mostly at nurses working in the operating room

Since 1998 all infants vaccinated with HepB vaccine after delivery in Turkey.

HepB vaccination

Hepatitis B (HepB) recombinant vaccine

2 doses 4 weeks apart; third dose 5 months after second (0., 1., 6. months scheme)

- booster doses not necessary;
- all doses should be administered IM in the deltoid

Preexposure: HCP at risk for exposure to **blood or body fluids**; postexposure



Reduces absenteeism and transmission of infection
 to hospitalized patients (air-droplet route).

Annual vaccination with	All HCP
current seasonal vaccine	
(before Oct, as well to May).	
	Annual vaccination with current seasonal vaccine (before Oct, as well to May).



- Risk of acquiring measles in hospital personnel is estimated to be 13 times greater
 - All transmissible by the air-droplet route,
 - Measles and varicella also by the air-borne and person to person !

Nosocomial outbreaks !

Measles-Mumps- Rubella livevirus vaccine	 2 doses SC; ≥28 days apart 	 for all HCP who lack presumptive evidence of immunity, should be considered for those born before 1957.
Varicella vaccine (varicella zoster virus live-virus vaccine)	 2 doses SC 4-8 weeks apart 	 all HCP who do not have evidence of immunity



- The immunity for Td decreases with aging.
- Pertussis is highly contagious with secondary attack rates and the incidence of pertussis has been increasing.

Tetanus and diphtheria (toxoids) and acellular	 1 dose IM as soon as feasible if Tdap not already received and regardless of interval from last Td. 	All HCP, regardless of age.
pertussis (Tdap)	 After receipt of Tdap, receive Td for routine booster every 10 years. 	

At-risk

HCP should be offered:

- polio,
- meningococcal,
- pneumococcal,
- Hib,
- BCG,
- rabies,
- typhoid,
- hepA.



All adults should be vaccinated against vaccinepreventable infections



- such as patient reminder/recall systems,
- healthcare system-based interventions,
- ensuring patients' vaccination needs.

Compliance with the vaccine recommendation

Patient attitude	Physicians' recommendation	Vaccination ratio %	
Positive	No	7	
Negative	Yes	63	
Positive	Yes	84 !!!	
Adapted from MMWR 1998;37: 657			

Physicians' recommendations influence patients' decision to recieve vaccine, regardless of the patients' initial attitude.



- Ann Intern Med. 2020;172:337-347. doi:10.7326/M20-0046.
- <u>https://www.cdc.gov/vaccines/schedules/hcp/imz</u> /adult.html
- <u>www.uptodate.com</u>
- <u>https://www.cdc.gov/mmwr/preview/mmwrhtml/rr</u>
 <u>6007a1.htm</u>